Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 12 October, 2012 and appeared in  PreventionPractice MgmtPublic HealthIssue 647

Diabetes Screening May Not Reduce Death Rates

Without the knowledge of what to do once diagnosed, nothing really happens....
Advertisement

Researchers looked at the number of deaths over 10 years among more than 20,000 people, aged 40 to 69. All of them were at high risk for diabetes.

The patients were divided into three groups. One group underwent a round of diabetes screening that was followed up by routine care for those diagnosed with diabetes; another group had a round of screening followed by intensive management for those diagnosed with diabetes; and a third group did not undergo diabetes screening.

Over an average follow-up of nearly 10 years, the overall death rates in the groups that had diabetes screening were no lower than in the group that had no screening. There also was no significant difference between the groups in the number of deaths specifically from diabetes, cardiovascular illness, cancer or other causes.

Study author Dr. Simon Griffin, of the epidemiology unit at Addenbrooke's Hospital in Cambridge, said in a journal news release, "It seems that the benefits of screening might be smaller than expected and restricted to individuals with detectable disease." "However, benefits to the population could be increased by including the detection and management of cardiovascular risk factors alongside the assessment of diabetes risk, performing repeated rounds of screening and improving strategies to maximize the uptake of screening."

Michael Engelgau, of the U.S. Centers for Disease Control and Prevention, wrote in an accompanying editorial, "Diabetes screening and diagnosis can be done with relative ease, which further escalates popular support for wide-scale screening." "However, these compelling arguments overlook the screening costs, potential harm and lack of clear evidence that screening improves health outcomes compared with current routine clinical diagnosis."

"This study increases the doubt about the value of wide-scale screening for undiagnosed diabetes alone, and deserves credit for tackling the screening quandary head-on," Engelgau concluded. "Nevertheless, for any one study to address the diverse factors that affect screening policies -- ranging from the magnitude of population burden of disease to the capacity and effectiveness of prevention approaches -- is a tall order. Screening recommendations are therefore likely to be country specific and context specific for the foreseeable future."

The Lancet, news release, Oct. 3, 2012  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 October, 2012 and appeared in  PreventionPractice MgmtPublic HealthIssue 647

Past five issues: Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 | Diabetes Clinical Mastery Series Issue 205 | Humulin Insulin Special Edition September 2014 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
Sensor Implant Measures Blood pH in Type 1 Diabetes
Posted August 29, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Diabetes in Control is considering launching a store tab on the site with the ability to purchase A1C tests and other diagnostic test in bulk for medical professionals. What do you think?
CME/CE of the Week
Hugh G. Calkins, MD, and Joseph Edward Marine, MD

Category: Cardiology
Credits:
 1
Search Articles On Diabetes In Control